Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review

Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review

The Programmed death-1 (PD-1) and its programmed death-ligand 1 (PD-L1) comprise the PD-1/PD-L1 axis and maintain tumor immune evasion. Cancer immunotherapy based on anti-PD-1/PD-L1 antibodies is the most promising anti-tumor treatment available but is currently facing the thorny problem of unsatisf...

Full description

Bibliographic Details
Main Authors:	Huilan Zheng, Gang Wang, Ming Liu, Hongbin Cheng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-06-01
Series:	Frontiers in Oncology
Subjects:	traditional Chinese medicine cancer immunotherapy sensitization immune checkpoint inhibitor PD-1/PD-L1 axis
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1168226/full

Similar Items

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

Cancer immunotherapies targeting the PD-1 signaling pathway
by: Yoshiko Iwai, et al.
Published: (2017-04-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01)

Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
by: Ofek Mussafi, et al.
Published: (2022-08-01)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
by: Edyta Zyla, et al.
Published: (2021-08-01)

PD-1/PD-L1 axis in organ fibrosis
by: Youliang Zhao, et al.
Published: (2023-05-01)

Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
by: Yu Yuan, et al.
Published: (2021-02-01)

Editorial: Natural products modulate the sensitivity of cancer to anti-PD-1 based immunotherapy
by: Jean Christopher Chamcheu, et al.
Published: (2023-06-01)

Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma
by: Huiyu Yan, et al.
Published: (2023-10-01)

Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
by: Grace Wakabayashi, et al.
Published: (2019-12-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
by: Tianrui Yang, et al.
Published: (2021-02-01)

Mouse Preclinical Cancer Immunotherapy Modeling Involving Anti-PD-1 Therapies Reveals the Need to Use Mouse Reagents to Mirror Clinical Paradigms
by: Arta M. Monjazeb, et al.
Published: (2021-02-01)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
by: Tingxuan Gu, et al.
Published: (2023-05-01)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
by: Long Jia, et al.
Published: (2018-06-01)

PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
by: Xiaohui Ren, et al.
Published: (2024-04-01)

Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy
by: Tao Wang, et al.
Published: (2022-05-01)

PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
by: Adil Parvez, et al.
Published: (2023-12-01)

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
by: Seri Jeong, et al.
Published: (2021-10-01)

Pulmonary blastoma treatment response to anti-PD-1 therapy: a rare case report and literature review
by: Yalin Xie, et al.
Published: (2023-04-01)

Mechanism and Clinical Application of PD-1/PD-L1 Inhibitors in Immunotherapy
by: Yang Xicheng
Published: (2022-01-01)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
by: Yiru Long, et al.
Published: (2022-05-01)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
by: Qian Li, et al.
Published: (2022-12-01)

Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges
by: Sadique A. Javed, et al.
Published: (2024-04-01)

Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
by: Sebastian Chrétien, et al.
Published: (2019-05-01)

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
by: Daixi Ren, et al.
Published: (2020-01-01)

Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
by: Jia-Wen Cui, et al.
Published: (2024-02-01)

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
by: Arefeh Zabeti Touchaei, et al.
Published: (2024-03-01)

Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
by: Peng Ding, et al.
Published: (2023-05-01)

IMMUNE RESISTANCE VIA A PD-1/PD-L1 MECHANISM IN GLIOBLASTOMA
by: V.S. KUSHNIROVA, et al.
Published: (2023-12-01)

Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era
by: SHAN Baoen
Published: (2023-09-01)

Novel nanotherapeutics for cancer immunotherapy by albumin nanoparticles functionalized with PD-1 and PD-L1 aptamers
by: Qiping Jiang, et al.
Published: (2024-01-01)

Advances in the Study of Hyperprogression of Different Tumors Treated with PD-1/PD-L1 Antibody and the Mechanisms of Its Occurrence
by: Jianpei Zheng, et al.
Published: (2023-02-01)

Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors
by: Shifaa M. Abdin, et al.
Published: (2018-01-01)

Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials
by: C. Bryce Johnson, et al.
Published: (2018-04-01)

Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points
by: Janina Świderska, et al.
Published: (2021-12-01)

The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy
by: Linda Quatrini, et al.
Published: (2020-11-01)

Immunotherapy using PD‑1/PDL-1 inhibitors in triple‑negative breast cancer: a systematic review
by: Dione Tavares, et al.
Published: (2021-12-01)

Beyond Cancer: Regulation and Function of PD-L1 in Health and Immune-Related Diseases
by: Amke C. Beenen, et al.
Published: (2022-08-01)

Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis
by: Fabian Krutzek, et al.
Published: (2022-06-01)

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
by: Xianjing Chu, et al.
Published: (2023-06-01)